Shares of Theravance Biopharma (TBPH 3.12%) were mauled in September, along with most other biotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.

Despite releasing some good news, a rough month for biotech stocks in general crushed the company's stock.
Shares of Theravance Biopharma (TBPH 3.12%) were mauled in September, along with most other biotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.